» Articles » PMID: 34011976

Involvement of the Dopaminergic System in the Reward-related Behavior of Pregabalin

Abstract

There has been an increase in cases of drug addiction and prescription drug abuse worldwide. Recently, pregabalin abuse has been a focus for many healthcare agencies, as highlighted by epidemiological studies. We previously evaluated the possibility of pregabalin abuse using the conditioned place preference (CPP) paradigm. We observed that a 60 mg/kg dose could induce CPP in mice and that pregabalin-rewarding properties were mediated through glutamate neurotransmission. Notably, the dopaminergic reward circuitry is also known to play a crucial role in medication-seeking behavior. Therefore, this study aimed to explore the possible involvement of dopaminergic receptor-1 in pregabalin-induced CPP. Mice were randomly allocated to receive saline or the dopamine-1 receptor antagonist SKF-83566 (0.03 mg/kg, intraperitoneal). After 30 min, the mice received either saline or pregabalin (60 mg/kg) during the conditioning phase. Among the control groups that received saline or SKF-83566, the time spent in the two conditioning chambers was not significantly altered. However, among the pregabalin-treated group, there was a marked increase in the time spent in the drug-paired chamber compared to the time spent in the vehicle-paired chamber. Notably, blocking dopamine-1 receptors with SKF-83566 completely prevented pregabalin-induced place preference, thus demonstrating the engagement of the dopaminergic system in pregabalin-induced reward-related behavior.

Citing Articles

Oral self-administration of pregabalin in a mouse model and the resulting drug addiction features.

Althobaiti Y Saudi Pharm J. 2024; 32(2):101935.

PMID: 38292403 PMC: 10825552. DOI: 10.1016/j.jsps.2023.101935.


The association between Gabapentin or Pregabalin use and the risk of dementia: an analysis of the National Health Insurance Research Database in Taiwan.

Huang Y, Pan M, Yang H Front Pharmacol. 2023; 14:1128601.

PMID: 37324474 PMC: 10266423. DOI: 10.3389/fphar.2023.1128601.


The Influence of Prenatal Exposure to Quetiapine Fumarate on the Development of Dopaminergic Neurons in the Ventral Midbrain of Mouse Embryos.

Alsanie W, Abdelrahman S, Alhomrani M, Gaber A, Alosimi E, Habeeballah H Int J Mol Sci. 2022; 23(20).

PMID: 36293205 PMC: 9603924. DOI: 10.3390/ijms232012352.


Prenatal Exposure to Gabapentin Alters the Development of Ventral Midbrain Dopaminergic Neurons.

Alsanie W, Abdelrahman S, Alhomrani M, Gaber A, Habeeballah H, Alkhatabi H Front Pharmacol. 2022; 13:923113.

PMID: 35942222 PMC: 9356305. DOI: 10.3389/fphar.2022.923113.


The Effects of Prenatal Exposure to Pregabalin on the Development of Ventral Midbrain Dopaminergic Neurons.

Alsanie W, Alhomrani M, Gaber A, Habeeballah H, Alkhatabi H, Felimban R Cells. 2022; 11(5).

PMID: 35269474 PMC: 8909856. DOI: 10.3390/cells11050852.

References
1.
Fritts M, Mueller K, Morris L . Amphetamine-induced locomotor stereotypy in rats is reduced by a D1 but not a D2 antagonist. Pharmacol Biochem Behav. 1998; 58(4):1015-9. DOI: 10.1016/s0091-3057(97)00308-0. View

2.
Boschen M . A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. Can J Psychiatry. 2011; 56(9):558-66. DOI: 10.1177/070674371105600907. View

3.
Kim H, Jang C, Park W . Inhibition by MK-801 of morphine-induced conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice. Pharmacol Biochem Behav. 1996; 55(1):11-7. DOI: 10.1016/0091-3057(96)00078-0. View

4.
Peng X, Li X, Li J, Ramachandran P, Gagare P, Pratihar D . Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats. Drug Alcohol Depend. 2007; 97(3):207-15. PMC: 2574799. DOI: 10.1016/j.drugalcdep.2007.09.019. View

5.
Zocchi A, Pert A . Increases in striatal acetylcholine by SKF-38393 are mediated through D1 dopamine receptors in striatum and not the frontal cortex. Brain Res. 1993; 627(2):186-92. DOI: 10.1016/0006-8993(93)90319-i. View